Vascular disrupting activity of combretastatin analogues (Q38767839)

6 September 2017

title

Vascular disrupting activity of combretastatin analogues (English)

1 reference

6 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27235861%20AND%20SRC:MED&resulttype=core&format=json

Stefania Maria Filomena Mitola

7 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27235861%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27235861%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27235861%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Giuseppe Basso

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27235861%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Alessia Salvador

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27235861%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Irina Primac

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27235861%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Cosetta Ravelli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27235861%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Roberta Bortolozzi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27235861%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Daniela Vedaldi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27235861%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Romeo Romagnoli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27235861%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

publication date

25 May 2016

1 reference

6 September 2017

published in

Vascular Pharmacology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27235861%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27235861%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

page(s)

78-89

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27235861%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

cites work

Vascular damaging agents

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.05.006

Anti-angiogenesis in cancer therapy: Hercules and hydra

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.05.006

The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.05.006

Recent advances in vascular disrupting agents in cancer therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.05.006

Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.05.006

Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.05.006

Vinca alkaloids: anti-vascular effects in a murine tumour

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.05.006

The biology of the combretastatins as tumour vascular targeting agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.05.006

Medicinal chemistry of combretastatin A4: present and future directions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.05.006

Design of combretastatin A-4 analogs as tubulin targeted vascular disrupting agent with special emphasis on their cis-restricted isomers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.05.006

Disrupting tumour blood vessels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.05.006

Synthesis and evaluation of 1,5-disubstituted tetrazoles as rigid analogues of combretastatin A-4 with potent antiproliferative and antitumor activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.05.006

Synthesis and antitumor activity of 1,5-disubstituted 1,2,4-triazoles as cis-restricted combretastatin analogues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.05.006

2-Arylamino-4-amino-5-aroylthiazoles. "One-pot" synthesis and biological evaluation of a new class of inhibitors of tubulin polymerization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.05.006

[4-(imidazol-1-yl)thiazol-2-yl]phenylamines. A novel class of highly potent colchicine site binding tubulin inhibitors: synthesis and cytotoxic activity on selected human cancer cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.05.006

TR-644 a novel potent tubulin binding agent induces impairment of endothelial cells function and inhibits angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.05.006

A new image analysis method based on topological and fractal parameters to evaluate the angiostatic activity of docetaxel by using the Matrigel assay in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.05.006

Vitronectin increases vascular permeability by promoting VE-cadherin internalization at cell junctions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.05.006

A critical analysis of current in vitro and in vivo angiogenesis assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.05.006

The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.05.006

Endothelial cadherins and tumor angiogenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.05.006

VE-cadherin: at the front, center, and sides of endothelial cell organization and function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.05.006

Focal adhesion kinase: in command and control of cell motility

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.05.006

VEGF binding to NRP1 is essential for VEGF stimulation of endothelial cell migration, complex formation between NRP1 and VEGFR2, and signaling via FAK Tyr407 phosphorylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.05.006

VEGF-induced vascular permeability is mediated by FAK.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.05.006

Focal adhesion kinase and tumour angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.05.006

Interference with endothelial cell function by JG-03-14, an agent that binds to the colchicine site on microtubules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.05.006

The microtubule binding drug laulimalide inhibits vascular endothelial growth factor-induced human endothelial cell migration and is synergistic when combined with docetaxel (taxotere).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.05.006

New oxazole-bridged combretastatin A-4 analogues as potential vascular-disrupting agents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.05.006

Effects of the novel vascular targeting agent MDS-11P on tumor vascularity and its antitumor activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.05.006

Antivascular actions of microtubule-binding drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.05.006

Anti-angiogenic and vascular disrupting effects of C9, a new microtubule-depolymerizing agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.05.006

Breaking the VE-cadherin bonds.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.05.006

Tyrosine phosphorylation of VE-cadherin prevents binding of p120- and beta-catenin and maintains the cellular mesenchymal state

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.05.006

Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.05.006

The chicken chorioallantoic membrane model in biology, medicine and bioengineering

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2016.05.006

10.1016/J.VPH.2016.05.006

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27235861%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27235861%20AND%20SRC:MED&resulttype=core&format=json